People · Operator
Named in public records as an officer, director or promoter · active 2015–2021 · Healthtech, Software / Tech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Imperative Care, Inc. | — | Healthtech | Series D+ | $584.7M | $712.6M | 2019 |
| JenaValve Technology Inc | — | Software / Tech | Series D+ | $328.5M | $2.2B | 2020 |
| Affinivax, Inc. | — | Biotechnology | Series D+ | $233.0M | $7.8B | 2021 |
| Xilio Therapeutics, Inc. | — | Biotechnology | Series C | $145.2M | $3.0B | 2021 |
| Editas Medicine, Inc. | — | Biotechnology | Series D+ | $120.0M | $4.9B | 2015 |
Andrew Hack at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Hack on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| DAVID GARDNER | 1 | 20 |
| Michael Ross | 1 | 18 |
| Peter Barrett | 1 | 18 |
| Kevin Bitterman | 1 | 15 |
| FARHAD KHOSRAVI | 1 | 14 |
| Tara Butler | 1 | 12 |
| Robert Weisskoff | 1 | 12 |
| Robert Mitchell | 1 | 9 |
| Henry Chen | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Robert More | 1 | 7 |
| Alexis Borisy | 1 | 6 |
| Amar Sawhney | 1 | 6 |
| David Grayzel | 1 | 6 |
| Douglas Cole | 1 | 5 |
| Evan S. Melrose | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| STACY ENXING SENG | 1 | 5 |
| Hank Plain | 1 | 5 |
| Quan Zhou | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.